Yusen Logistics expands cold storage in Belgium and the Netherlands

By Flora Southey contact

- Last updated on GMT

Yusen Logistics expands cold storage in Belgium and the Netherlands

Related tags: Active ingredient, Logistics

Yusen Logistics has announced plans to increase cold storage facilities in Belgium and the Netherlands in an investment of more than €10m ($10.8m). 

Both facilities will consist of cold storage (2-8⁰) and ambient (15-25⁰) zones.

“We notice the requirement, by all our customers, to have both storage possibilities (ambient and cold). So when we expand, we need to expand in both,”​ said Yusen Logistics (YL) Director of Contract Logistics, Hugo Van Herck.

Van Herck told Outsourcing-Pharma the new facilities will have the capacity to store both Active Pharmaceutical Ingredients (APIs) and finished products, including narcotics.

The project includes the construction of a 8,000 sq.meter adjoining warehouse at its Melsele facility near Antwerp, Belgium, and a new, 11,225 sq.meter facility near Roosendaal in the Netherlands.

“The enlarged capabilities will also create new jobs”​ said Van Herck.

The current Melsele facility, a 18,000 sq.meter warehouse including 1,500 cold store pallet positions, serves as the company’s central European hub. The expansion, to be operated by the existing team, will be open for business by the end of 2017.

The Roosendaal facility was planned in response to an increased demand for pharmaceutical and healthcare industry storage needs in the region. “Recently, an existing customer requested YL to set up a high-qualified pharma logistics operation in the Netherlands, and this was the trigger for YL to take the next step”​ said Van Herck. The Roosendaal depot will be open for business early 2018.

The warehouses, which represent an investment of more than €10m ($10.8m) investment, will be built by development companies and leased to YL.

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars